Halozyme Therapeutics Inc

HALO is in a Stage 2 advancing corrective reset with a medium-term bullish bias supported by a clear higher-highs and higher-lows sequence and an active Bullish Pivot Point. Price has accepted and reclaimed the rising 9EMA/21EMA and 50DMA following a shallow pullback, favoring continuation participation. Despite an overbought reading, the near-term trend remains constructive, but flattening EMAs and failure to clear recent highs pose risks.

• ↑Total revenue +42% YoY to $377M driven by 43% royalty growth
• ↑Adjusted EBITDA +42% to $230M indicates exceptional margins and cash flow
• ↓Negative book-to-price valuation and weak dividend yield suggest overvaluation